Stifel raised the firm’s price target on Glaukos (GKOS) to $160 from $115 and keeps a Buy rating on the shares. The firm’s Epioxa survey work was better-than-anticipated, says the analyst, who revamped the firm’s Epioxa sales build and arrives at 2027/2028 U.S. Epioxa sales estimates of $272M and $571M, respectively. Holding all else equal, this would drive a revenue growth acceleration from 25% year-over-year in 2026 to 46% and 45% in 2027 and 2028, respectively, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors
- Glaukos falls -8.5%
- Video: Wells Fargo dips as big bank earnings continue
- Maintaining a Buy on Glaukos: Near‑Term iDose Reset but Strong Core Business and Epioxa-Driven Long‑Term Upside
- Closing Bell Movers: Glaukos slips 13% after pre-announcement